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Abbreviations. CAP, community-acquired pneumonia; AKI, acute kidney injury; NP, 
natriuretic petide; NT-proBNP, N-terminal pro B-type natriuretic peptide; MR-proANP, 
mid-regional pro-atrial natriuretic peptide; BNP, B-type natriuretic peptide; HIV, 
human immunodeficiency virus; ED, emergency department; AKIN, Acute Kidney 
Injury Network classification; PSI, pneumonia severity index; CURB-65, confusion, 
urea plasma level, respiratory rate, blood pressure, age over 65 years; EDTA, 
ethylenediaminetetraacetic acid; AUC, area under the curve; CKD, chronic kidney 
disease; CRP, C-reactive protein; ROC, receiver operating characteristic; CI, 
confidence interval; HR, hazard ratio; OR, odds ratio; TNF, tumor necrosis factor; IL, 
interleukin; mRNA, messenger ribonucleic acid; proANP, pro-atrial natriuretic peptide.  
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Abstract 
Background: Community-acquired pneumonia (CAP) is common and associated 
with a considerable risk of acute kidney injury (AKI).  
Methods. We prospectively enrolled 341 patients presenting to the emergency 
department with CAP (mean age 72, male 61%). Blinded measurements of three 
natriuretic peptides (NT-proBNP, MR-proANP and BNP) were performed upon 
presentation. The primary endpoint was the accuracy of the natriuretic peptides to 
predict AKI within 48 hours.   
Results. AKI occurred in 24 patients (7.6%) within the first 48 hours. NPs and 
creatinine were significantly higher in AKI compared with patients without AKI (NT-
proBNP 9517 [2042-26792] vs 1177 [280-4167] pg/ml; MR-proANP 641 [196-1075] 
vs 182 [99-352] pmol/l; BNP 592 [230-1630] vs 160 [64-463] pg/ml; creatinine 166 
[131-289] versus 100 [78-134] µmol/L, P<0.001 for each). Predictive accuracy as 
quantified by the area under the receiver operating characteristics curve was 
moderate to high: NT-proBNP 0.79 (95%CI 0.70-0.88), MR-proANP 0.78 (95%CI 
0.67-0.88), BNP 0.74 (95%CI 0.63-0.85), creatinine 0.77 (95%CI 0.66-0.88). In 
multivariate logistic regression analysis, NPs remained the only independent AKI 
predictors: NT-proBNP (increase of 200 pg/ml) OR=1.01, 95%CI 1.00-1.01, P=0.009; 
MR-proANP (increase of 100 pg/ml) OR=1.23, 95%CI 1.09-1.39, P=0.001; BNP 
(increase of 100 pg/ml) OR=1.08, 95%CI 1.03-1.14, P=0.002. 
Conclusions. NP levels are significantly elevated in CAP-patients experiencing early 
AKI. Their potential to predict early AKI is comparable to serum creatinine and might 
be useful in cases of diagnostic uncertainty. 
 
Keywords: acute renal failure, natriuretic peptides, community-acquired pneumonia. 
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Highlights 
• Community-acquired pneumonia (CAP) is associated with a considerable risk 
of acute kidney injury (AKI) 
• We prospectively enrolled 341 patients presenting to the emergency 
department with CAP 
• Natriuretic peptides were accurate predictors of early in-hospital AKI 
• Due to the high incidence of CAP and the prognostic importance of CAP-
associated AKI, its early recognition is of great clinical importance. 
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1. Introduction 
Community-acquired pneumonia (CAP) is a common infectious cause of 
hospitalization in developed countries. Between 1998 and 2002, CAP was the 
primary reason for 5.8% of all United States Medicare hospitalizations and 
contributed to almost 10% of in-hospital stays [1]. CAP-associated AKI is of great 
clinical importance: CAP patients suffering from AKI are more likely to require 
medical intensive care, have longer hospital stays and suffer from increased in-
hospital and long-term mortality [2, 3]. Hence, a rapid and reliable predictor of AKI 
might help physicians in the early identification of patients requiring closer monitoring 
and possibly benefiting from adequate hydration and avoidance of nephrotoxic 
treatments. Importantly, sepsis-induced AKI appears to have a distinct 
pathophysiology and identity, with the extent of cardiac stress and inflammation 
acting as primary triggers [4].  
Natriuretic peptides (NPs), a family of ring-shaped vasoactive hormones with 
considerable sequence homology, have repeatedly been shown to be increased in 
salt- and water-retaining states, such as heart failure or AKI, in an attempt to 
overcome the salt and water retention via their natriuretic and diuretic properties [5, 
6]. Their levels have consistently been shown to mirror the extent of cardiac stress in 
various disease states [5, 6]. Additionally, pro-inflammatory cytokines and the 
activation of the sympathetic nervous system have recently been identified as 
triggers of NP secretion [7].  
Consequently, NP levels may integrate the severity of cardiac stress and the 
inflammatory cytokine response as important triggers of sepsis-induced AKI. 
Therefore, we aimed to evaluate and directly compare the potential of three NPs to 
predict the occurrence of AKI in patients with CAP.  
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2. Materials and Methods  
This study specifically investigated the potential of plasma NT-proBNP, MR-proANP 
and BNP levels to predict early AKI in hospitalised patients with CAP. We screened 
422 consecutive patients presenting with suspected CAP from November 2003 to 
March 2007 for enrolment into this study [8-10]. Due to lack of resources, recruitment 
was interrupted from February 2005 to April 2006. The study was carried out 
according to the principles of the Declaration of Helsinki and approved by the local 
ethics committee. Written informed consent was obtained from all participating 
patients. 
 
2.1. Setting and study population 
To be eligible for enrolment into the trial, patients had to be over 18 years old and be 
able to give a written consent. Consecutive CAP patients were asked to participate in 
the study and to give informed consent shortly after presentation to the hospital. 
Patients with cystic fibrosis, active pulmonary tuberculosis, hospital-acquired 
pneumonia, severely immunocompromized patients (HIV, active chemotherapy, solid 
organ transplant, on methotrexate, azathioprine, cyclosporin, or anti-tumor necrosis 
factor-α) and patients undergoing chronic dialysis were excluded. Community-
acquired pneumonia was defined as a new infiltrate on chest radiograph and history 
consistent with pneumonia with 3 or more of the following newly acquired  features: 
cough, sputum production, dyspnea, core body temperature exceeding 38.0°C, 
auscultatory findings of abnormal breath sounds and rales, and leukocyte count 
greater than 10x109 or less than 4x109 cells L–1 [11]. CAP was confirmed after review 
of all medical records pertaining to the patients at a follow-up clinic review. No single 
biomarker or pre-specified biomarker level was necessary for the diagnosis of CAP. 
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Similarly, the initiation of antibiotic therapy was not necessary for the diagnosis of 
CAP. 
 
2.2. Site of care 
Patients presented either as general practitioner referrals or as self-referrals to the 
ED. Patients were examined on presentation to the emergency department by a 
resident supervised by a board-certified specialist in internal medicine. The choice of 
antibiotic regimen was left to the discretion of the treating physician and was made in 
accordance with locally-approved antimicrobial guidelines. The exact antibiotic 
regimen and treatment duration as well as results of microbiology testing were 
documented. Antibiotic treatment was defined as appropriate if the agent was chosen 
in accordance with locally-approved guidelines and the antibiotics initially chosen 
covered the microorganisms obtained from microbiology studies. In the case of 
negative microbiology results, antibiotic treatment was defined as appropriate if the 
regimen was chosen in accordance with the guidelines. Antibiotic treatment was 
defined as inappropriate if the choice of regimen was not in accordance with the 
guidelines or if the antibiotic agent initially chosen did not cover the microorganisms 
obtained from the microbiology studies. The study investigators were neither directly 
involved in patient care in the ED nor did they have any influence on the decision to 
discharge patients from the ward.  
 
 
2.3. Study protocol 
All patients were subject to an initial clinical assessment including medical history, 
physical examination, electrocardiography, pulse oximetry, blood tests including 
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arterial blood gas analysis (when indicated) and chest x-ray. Demographics and co-
morbidities including the presence of chronic kidney disease were recorded on the 
ED upon arrival. The medical history was recorded from patient history, 
documentation of prior admissions and completed using general practitioners` 
documentation.  
Long-term survival was assessed during a one-time telephone contact. If the patient 
could not be contacted, family members, general practitioners and the local registry 
office were contacted to confirm the survival status of the patient.  
2.4. Renal failure and severity of illness 
We defined AKI according to the Acute Kidney Injury Network (AKIN) classification as 
an in-hospital increase in creatinine greater than 26.4 µmol/l (0.3mg/dl) occurring 
during the first 48 hours, which persisted after adequate volume resuscitation [12]. 
The potential of presentation NP levels to predict early AKI was assessed as the 
primary endpoint.  
PSI is a clinical prediction index used to calculate the probability of mortality among 
patients with CAP. The rule uses demographics, co-morbid illnesses, findings on 
physical examination, vital signs and laboratory findings. PSI allows stratification into 
five risk categories [13]. CURB-65 is another morbidity prediction index. The score is 
an acronym for each of the risk factors measured: confusion, urea plasma level, 
respiratory rate, blood pressure and age over 65 years. Each risk factor scores one 
point, for a maximum score of 5 [14]. 
 
2.5. Measurements of MR-proANP, NT-proBNP and BNP 
At presentation to the ED, blood samples were collected into bottles containing 
potassium EDTA. After centrifugation samples were immediately frozen at −80°C 
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until later analysis. Plasma biomarker concentrations were measured in a blinded 
fashion. Detection of MR-proANP was performed using a sandwich immunoassay 
(MR-proANP LIA, B.R.A.H.M.S, Hennigsdorf ⁄ Berlin, Germany). NT-proBNP levels 
were determined by a quantitative electrochemiluminescence immunoassay (Elecsys 
proBNP; Roche Diagnostics AG, Zug, Switzerland). BNP was detected in EDTA 
plasma with a flurescence immunoassay (Biosite Diagnostics, La Jolla, CA, USA). 
The serial creatinine measurements were performed with the chromogenic Jaffe`s 
reaction.  
2.6. Statistical analyses 
Categorical variables are expressed as counts (percentage) and continuous variables 
as median and interquartile ranges. Correlation analyses were performed using 
Spearman rank correlation. Comparisons between variables and outcome were 
made using the Student t-test, the Kruskal–Wallis test, the Mann–Whitney U-test and 
the chi-squared test as appropriate. AUC were compared using MedCalc software 
(version 9.2.; MedCalc Software, Mariakerke, Belgium). The potential of NP levels at 
presentation to predict AKI was assessed as the endpoint. To estimate the potential 
clinical relevance of biomarker measurements we used logistic regression models. 
We evaluated the incremental value of NPs to traditional AKI predictors. As traditional 
parameters, we defined a base set consisting of serum creatinine, pre-existing renal 
disease and pneumonia severity expressed in PSI points. These variables have been 
associated with AKI and mortality in patients with pneumonia in previous studies [2] 
and were significantly different in the patients group with AKI versus without AKI in 
this cohort. We then compared the performance of the base set alone with its 
performance after adding the NPs. Statistical analyses were performed using 
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SPSS/PC (version 19.0; SPSS Inc., Chicago, IL, USA) software package. A statistical 
significance level of 0.05 was used. All hypothesis testing was two-tailed. 
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3. Results 
3.1. Baseline characteristics and clinical outcome:  
A total of 422 patients were enrolled in this study. Baseline values from all three NPs 
were available for 341 of the 422 consecutive patients. These 341 patients 
constituted the study population included in analysis. The baseline characteristics 
and antibiotic treatment of the study population are displayed in Table 1. The median 
follow-up time was 942 days [366-1626]. In-hospital and long-term follow-up were 
complete in 100% of the patients. We also assessed the predictive potential of NPs 
for short- and long-term mortality and describe the results elsewhere [15].  
The mean age was 72 years and there were 209 men (61%). Overall, 24 (7.6%) 
patients developed AKI during the first 48 hours of the index hospitalisation. Of these 
24 patients, 5 required renal replacement therapy (RRT) during the index 
hospitalisation. There were no differences in patients with AKI versus without AKI in 
respect to gender, vital signs, antibiotic treatment, its appropriateness and antibiotic 
class. Patients with known CKD, hypertensive heart disease and older patients 
developed AKI more frequently. AKI was associated with short- and long-term 
mortality (44% non-AKI vs. 67% AKI patients died) (Table 1).  
 
3.2. Plasma NP levels in patients experiencing acute kidney injury: 
NP levels in this cohort of CAP patients correlated significantly with disease severity 
classified by pneumonia severity index (PSI) points (NT-proBNP: r=0.532, P<0.001; 
MR-proANP: r=0.567, P<0.001; BNP: r=0.467, P<0.001). Patients experiencing early 
AKI suffered more severe CAP according to PSI points (Table 1). The highest 
presentation levels of NPs were observed in early AKI patients subsequently 
requiring RRT, the lowest in patients without early AKI. Figure 1 shows presentation 
NT-proBNP levels as an example. For MR-proANP the medians were 182 [99-352] 
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pmol/l without AKI, 478 [156-475] pmol/l in AKI without RRT requirement; 2400 [761-
2495] pmol/l in AKI with RRT requirement, P<0.001; for BNP the medians were 160 
[64-463] pg/ml without AKI, 436 [197-1629] pg/ml with AKI without RRT, 1427 [592-
5311] pg/ml in AKI with RRT requirement, P<0.001). 
 While a weak albeit significant correlation also existed between PSI point values 
CRP levels (r=0.113, P=0.04) and leukocyte count (r=0.122, P=0.03), there was no 
difference in these markers between AKI and non-AKI patients (leukocyte count 
P=0.9; CRP P=0.67).  
 
 
3.3. Predictors of acute kidney injury 
To evaluate the potential of serum creatinine and the NP measurements at 
presentation to predict the occurrence of AKI, receiver operating characteristic (ROC) 
analyses were performed. The area under the ROC curve (AUC) for the prediction of 
AKI of NT-proBNP, MR-proANP and BNP was comparable to creatinine, as shown in 
Figure 2 and Table 3A. 
It must be noted that the predictive accuracy for AKI was consistent even after 
exclusion of 39 patients with a history of congestive heart failure (AUC NT-proBNP: 
0.79; 95%CI 0.69-0.89; AUC MR-proANP: 0.79; 95%CI 0.70-0.90; AUC BNP: 0.74; 
95%CI 0.63-0.86).  
We defined a base set of traditional parameters as consisting of serum creatinine, 
chronic kidney disease and pneumonia severity expressed in PSI. When entering 
these traditional parameters and the NPs into a univariate regression analysis, all the 
variables were predicitive for AKI (Table 2).  The antibiotic treatment and its 
appropriateness were not protective against AKI, as assessed by univariate logistic 
regression analysis.  
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To assess a possible incremental value of the NPs to the traditional predictive 
parameters, multivariate regression analysis was performed. We compared the 
performance of the base set alone with its performance after adding the NPs using 
ROC plot analysis (Table 3B). The AUC for base set alone was not significantly 
different after adding one of the three NPs. 
 
As a next step, we compared the accuracy of a three NPs model with the accuracy of 
single base set predictors (Table 3C). The AUC for the three NPs model was 
significantly larger than the AUCs for the clinical parameters CKD and pneumonia 
severity respectively. Furthermore, the AUC for the three NPs tended to be larger 
than for serum creatinine. 
After inclusion of the base set variables and one of the NPs in a multivariate 
regression, only the NP remained a significant AKI predictor (Table 2). Using the 
other two NPs in the same model, the predictive potential for MR-proANP [increase 
of 100 pmol/L] was HR 1.23, 95%CI 1.09-1.39, P=0.001; for BNP [increase of 100 
pmol/L]: HR 1.08, 95%CI 1.03-1.14, P=0.002). 
After exclusion of 38 patients with a history of congestive heart failure, the predictive 
ability of NPs remained consistent (NT-proBNP [for an increase of 200 pg/ml]: OR 
1.01, 95%CI 1.00-1.01, P=0.02; MR-proANP [for an increase of 100 pmol/L]: OR 
1.27, 95%CI 1.12-1.45, P<0.001; BNP [for an increase of 100 pg/ml]: OR 1.09, 
95%CI 1.03-1.15, P=0.004).  
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4. Discussion 
In this study, we examined the possible merit of plasma NP levels at presentation for 
the prediction of early AKI in 341 CAP patients. There are several key findings in this 
study. Firstly, NP levels at presentation where significantly higher in patients 
experiencing early AKI compared to non-AKI patients. Among the AKI patients, the 
highest NP levels were observed in patients who needed RRT in the course of 
hospitalization. Secondly, NP levels at presentation accurately predicted in-hospital 
AKI within the first 48 hours. Thirdly, the predictive potential of NP levels were 
independent of creatinine values at presentation and persisted after the exclusion of 
patients with a history of congestive heart failure.  
Our results represent the first large-scale study investigating the potential of plasma 
NPs for the prediction of AKI in the setting of CAP. This confirms and further extends 
our previous findings that NP levels at presentation powerfully predict mortality for 
CAP patients [15-17]. Infection-induced AKI has recently been proposed to be 
triggered by distinctly different pathophysiological patterns from non-infectious AKI. A 
recent study enrolling over 120 000 critically ill patients found that patients suffering 
from sepsis-induced AKI display more pronounced signs of cardiac stress, 
inflammation, renal and pulmonary impairment and disease acuity [4] compared to 
patients suffering from AKI of other causes.  
NPs are vasoactive hormones that have consistently been shown to mirror the extent 
of cardiac stress and strain [5, 6]. Consequently, the assessment of NPs has become 
a cornerstone in the management of heart failure patients [18-20] and is endorsed by 
heart failure guidelines [21]. While CAP patients do not display the overt clinical 
picture of heart failure characterised by fluid retention and inadequate perfusion of 
peripheral organs, CAP is a significant stressor to the cardiovascular system through 
low peripheral vascular resistance, increased cardiac output and the occurrence of 
 15 
arterio-venous shunts in inflamed areas [22]. Additionally, cardio-depressing effects 
have been described for pro-inflammatory mediators such as lipopolysaccharides 
[23], TNF-α and IL-1β [24, 25]. Hence, elevated NP levels in the setting of CAP 
appear to identify a patient subgroup with limited cardiac reserves. Increased cardiac 
stress propels these patients over the threshold at which elevated cardiac output and 
adequate renal oxygen supply can be maintained and peripheral vasoconstriction 
leading to low local renal perfusion and AKI occurs. By reflecting cardio-renal 
interactions, NP levels mirror derangements in an important pathophysiological 
pathway to inflammatory AKI. This type of cardio-renal interaction in which a systemic 
non-cardiac, non-renal condition affects both organs was recently termed the cardio-
renal syndrome Type 5 [26].  Supporting this hypothesis, another study with CAP 
patients and acute renal injury demonstrated an elevated neutrophil gelatinase-
associated lipocain (NGAL) as a marker of acute reno-tubular damage and 
simultaneously elevated natriuretic peptide levels as a marker of cardiac stress [27]. 
A further reason for elevated NP levels in CAP is their response to inflammatory 
stimuli. A small study enrolling septic patients found NP levels to positively correlate 
with CRP values while finding no correlation between systolic dysfunction measured 
by echocardiography and NP levels [28]. Moreover, pro-inflammatory cytokines such 
as IL-1β, IL-6 and TNFα have been shown to induce NP secretion from cultured 
myocytes in vitro [7, 29]. Concordantly, bacterial endotoxin was found to directly 
increase the expression of BNP mRNA in rat myocytes [30]. Thus NP levels appear 
to reflect the extent of systemic inflammation in CAP - an additional contributor to the 
pathogenesis of sepsis-induced AKI. 
Additionally, NP levels reflect the extent of relevant co-morbidities, especially renal 
dysfunction. As it is the case in our study, NP levels are consistently negatively 
correlated with kidney function [31]. As in our study, impaired baseline renal function 
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has repeatedly been associated with an increased risk of AKI in various settings [4, 
32]. However, besides purely reflecting baseline renal function, circulating NP levels 
might even be directly triggered by AKI. One older study examining 120 patients with 
differing degrees of renal impairment found urinary proANP levels to dramatically 
increase even before serum creatinine levels started to rise [33]. However, further 
studies concerning this observation are lacking. Hence, by integrating cardiac stress, 
inflammation and co-morbid burden of CAP patients, NP levels adequately predict 
early AKI with similar accuracy to serum creatinine. 
Due to the high incidence of CAP and the prognostic importance of CAP-associated 
AKI, early AKI recognition is of great clinical importance. By adequately predicting the 
occurrence of AKI, NPs could provide physicians with a “red flag” for the early 
initiation of renoprotective interventions: maintaining positive fluid balance, 
preventing contrast-induced nephropathy, avoiding any nephrotoxic drugs and 
pentastarch fluid resuscitation [34] and adjusting medication doses to renal function. 
Additionally, initial studies indicate that treatment options may become available to 
reverse AKI if promptly initiated [35]. Finally, early recognition of AKI might lead to a 
more timely involvement of the nephrology care team, which has been associated 
with improved patient outcome in intensive care unit patients developing acute renal 
failure [36].  
Several limitations merit consideration. First, this was a single center study. However, 
as baseline characteristics and mortality rates were similar to those of previous 
studies, we consider our results representative. Second, the incidence of AKI 
observed in our study was lower than observed in previous studies examining CAP 
patients [2, 3]. However, these studies either selectively evaluated community-
acquired AKI, which can easily be detected by serum creatinine measurements at 
presentation, or examined the prevalence of AKI in critically ill patients. The inclusion 
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of unselected CAP patients presenting to the emergency department and the 
observational period of 48 hours explain the lower AKI incidence in our study. In fact, 
a similar study assessing early AKI occurring within the first 72 hours after 
presentation to the emergency department found a comparable AKI incidence [37]. 
Third, treating physicians were blinded to the NP test results. We cannot therefore 
assess the impact of an NP guided treatment strategy on AKI rate and long-term 
outcome. To ascertain blinded measurements of NP levels, all samples had to be 
stored until after the conduction of the study. However, we feel that blinded NP 
measurements were necessary to rule out a treatment bias. Fourth, the different NPs 
display significantly different long-term stability during storage at -80°C, with NT-
proBNP and MR-proANP showing better stability then BNP [38]. As all samples were 
stored at -80° C until blinded batch analysis, we feel that the small trend towards 
predictive inferiority observed for BNP was probably caused by degradation of the 
detectable peptide during storage. 
In conclusion, natriuretic peptide levels are significantly elevated in CAP patients 
experiencing early AKI. Their potential to predict early AKI is comparable to serum 
creatinine and might be useful in cases of diagnostic uncertainty. 
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 Table 1. Patient`s characteristics and clinical outcome 
 All patients                      
 
No AKI 
 
AKI 
 
Number of patients – n (%)  341 
 
317 (92.4) 
 
24 (7.6)  
 
Age – years  
 
72 [63-82]    
 
75 [64-82] 
 
80 [71-86] 
 
Male – n (%) 209 (61)   
 
196 (62) 
 
12 (50) 
Disease severity 
 
 
   
PSI points 
 
 
103 [80-128] 102 [80-128] 117 [101-148] 
CURB-65 points 
 
 
2 [1-2] 2  [1-2] 2 [1-2] 
Comorbidities– n (%) 
 
   
Known chronic kidney 
disease  – n (%)  
95 (28)    
 
80 (25) 
 
15 (63) 
 
Congestive heart failure – n 
(%) 
39 (11) 
 
36 (11) 
 
3 (13) 
 
Coronary artery disease – n 
(%) 
103 (30)  
 
94 (30) 
 
9 (38) 
 
Cerebrovascular disease – n 
(%) 
24 (7) 
 
24 (7.6) 
 
0 (0) 
 
Hypertensive heart disease – 
n (%) 
82 (24) 
 
72 (23) 
 
10 (48) 
 
Neoplasia – n (%) 
 
63 (18) 
 
59 (19) 
 
4 (17) 
 
Diabetes mellitus – n (%) 69 (20) 62 (20) 
 
7 (29) 
Vital status 
 
   
Systolic blood pressure (mm 
Hg)     
132 [114-144] 130 [114-144] 
 
134 [113-153] 
 
Heart rate (beats/min) 
 
97 [82-111] 
 
98 [80-110] 
 
98 [80-110] 
 
Respiratory rate (breaths/min) 24 [20-28] 24 [20-28] 22 [20-28] 
 25 
    
Body temperature (°C)   
 
38.3 [37.5-39.1] 38.2 [37.5-39.1] 38.3 [37.4-38.7] 
Oxygen saturation (%) 92 [89-96] 
 
93 [89-96] 
 
91 [87-96] 
 
Laboratory values 
 
   
Creatinine (µmol/L) 
 
104 [ 80-143] 100 [78-134] 
 
166 [131-289] 
Outcome 
 
   
Days in hospital –  n (%) 
 
14 [8-18] 
 
13 [8-17] 
 
16 [8-21] 
 
ICU/HDU requirement 
 
26 (7.6) 25 (7.9) 5 (21) 
30d-mortality – n (%) 
 
38 (11) 
 
32 (10) 
 
6 (25) 
 
Mortality during follow-up –  n 
(%) 
 
154 (45) 
 
137 (43) 
 
17 (68) 
Antibiotic treatment 
 
   
Patients treated - n (%) 
 
320 (94) 296 (94) 24 (100) 
Patients appropriately treated 
- n (%  of all treated)   
 
310 (91) 286 (90) 24 (100) 
Antibiotic groups 
 
   
Penicillin 
 
253 235 18 
Cephalosporin 
 
84 
 
80 
 
4 
 
Macrolide 129 
 
120 
 
9 
 
Carbapenem 
 
8 8 0 
Gyrase inhibitor 
 
21 18 3 
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Others* 
 
9 1 8 
 
Legend. AKI, acute kidney injury; ICU, Intensive Care Unit; HDU high dependency 
Unit  
*Others=4xAminoglycosides; 2xThrimetoprin/Sulfomethoxazol; 1xRifampicine; 
1xClindamycine; 1xVancomycine 
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Table 2. Prediction of acute kidney injury development in logistic regression analysis 
Predictor  OR p-value 
Univariate logistic regression using base 
set* variables and NPs 
  
NT-proBNP1 1.01 (1.01-1.02) <0.001 
MR-proANP2 1.29 (1.17-1.43) <0.001 
BNP 3 1.09 (1.05-1.14) <0.001 
Creatinine4 1.01 (1.00-1.01) <0.001 
CKD 4.94 (2.08-11.72) <0.001 
PSI5 1.01 (1.00-1.02) 0.03 
Multivariate logistic regression using 
base set and NT-proBNP 
  
NT-proBNP1 1.01 (1.00-1.01) 0.009 
Creatinine2 1.00 (1.00-1.01) 0.07 
CKD  1.92 (0.65-5.66) 0.24 
PSI5 1.00 (0.99-1.02) 0.72 
* base set: serum creatinine, chronic kidney disease, pneumonia severity  
 
Legend: NT-proBNP, N-terminal pro brain natriuretic peptide; MR-proANP, 
midregional-pro atrial natriuretic peptide; BNP, brain natriuretic peptide; PSI, 
Pneumonia Severity Index  
 
1 increase of 200 pg/ml 
2 increase of 100 pmol/L 
3 increase of 100 pg/ml 
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4 increase of 1 µmol/L 
5 for each point
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Table 3. Prediction of acute kidney injury development in patients with community 
acquired pneumonia. Area under the curve of receiver operating curve characteristic 
(ROC) plot analysis  
Predictor 
A. Prediction by single 
biomarkers  
AUC 95% CI P comparison 
NT-proBNP 0.79 0.70-0.88 - 
MR-proANP 0.78 0.67-0.88 0.9 
Creatinine 0.77 0.66-0.88 0.59 
BNP 0.74 0.63-0.85 0.27 
B. Prediction by models: base 
set* and NPs 
   
Base set  0.75 0.63-0.86 - 
Base set and MR-proANP 0.78 0.67-0.88 0.28 
Base set and NT-proBNP 0.76 0.65-0.88 0.16 
Base set and BNP 0.76 0.64-0.87 0.55 
C. Prediction by three NPs model 
versus single base set variables  
   
Three NPs  0.79 0.69-0.89 - 
Creatinine 0.77 0.66-0.88 0.44 
CKD 0.69 0.57-0.80 0.003 
PSI   0.64 0.53-0.74 0.001 
* base set: serum creatinine, chronic kidney disease, Pneumonia severity  
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Legend. AUC, area under the curve; SD, standard deviation; CI, confidence interval; 
NT-proBNP, N-terminal pro brain natriuretic peptide; MR-proANP, midregional-pro 
atrial natriuretic peptide; BNP, brain natriuretic peptide; CKD, chronic kidney disease; 
PSI, Pneumonia severity Index  
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Figure legends 
Figure 1. Box plots showing NT-proBNP levels at presentation in patients with stable 
kidney function (n=317), acute kidney injury without renal replacement requirement 
(n=19) and with acute kidney injury with renal replacement requirement (n=5). 
 
Figure 2. Prognostic accuracy of NT-proBNP, MR-proANP, BNP, and eGFR to 
predict AKI. 
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Figure 1. Box plots showing NT-proBNP levels at presentation in patients with stable 
kidney function (n=317), acute kidney injury without renal replacement requirement 
(n=19) and with acute kidney injury with renal replacement requirement (n=5). 
 
 
 
 
 
 
Legend. AKI, acute kidney injury; eGFR, estimated glomerular filtration rate, NT-
proBNP, N-terminal pro brain natriuretic peptide; RRT, renal replacement therapy. 
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Figure 2. Prognostic accuracy of NT-proBNP, MR-proANP, BNP, and creatinine to 
predict AKI 
 
Legend. AKI, acute kidney injury; NT-proBNP, N-terminal pro brain natriuretic 
peptide; MR-proANP, midregional-pro atrial natriuretic peptide; BNP, brain natriuretic 
peptide  
 
 
